Traditional animal models remain an important part of preclinical research, but species differences can limit translation of ...

Alzheimer’s disease often overlaps with other causes of cognitive decline. A new proteomics project aims to untangle that ...

From AI agents to cell therapy to Alzheimer’s drug pipelines, this issue follows the same problem across three fields:what it takes to turn something that works once into something that works at scale ...

Priyom Bose earned her Ph.D. in Plant Biology and Biotechnology from the University of Madras, India, in 2019 before ...

Antibody discovery is becoming less about finding the strongest binder and more about finding molecules that can survive the journey to the clinic.

But NRTIs are known to have serious toxicities, so Ambati’s team created new chemical derivatives called kamuvudines that ...

New findings slowed tumor growth in a mouse model of triple-negative breast cancer, offering a new template for RNA drug ...

A win for autoimmune disease, a set back for Alzheimer’s disease, an FDA backing for a multi-cancer blood test, and more led ...

Mucopolysaccharidosis type IIIA (MPS IIIA), also known as Sanfilippo syndrome Type A, progressively destroys cognitive and motor function in early childhood through a single missing enzyme: ...

Welcome to the Weekly Rundown where the DDN editors cover this week’s top biotech and pharma news. Novo Nordisk taps Anthropic's Claude to speed drug discovery Novo Nordisk is partnering with ...

Computational antibody design has accumulated an enormous body of claims, with conference presentations, preprints, and company white papers describing model after model capable of producing ...

Welcome to the Weekly Rundown where the DDN editors cover this week’s top biotech and pharma news. Nanoscope advances gene-agnostic therapy for severe vision loss in RP The FDA has accepted Nanoscope ...